ArticleCureus2026
Impact of International Travel on Clinical Outcomes of Mpox Cases in Jeddah, Saudi Arabia: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSaudi Arabia is a global hub for air travel and mass gatherings; the first case of mpox in the Kingdom was linked to international travel. It is not clear whether travel-related mpox cases differ from locally acquired cases in how they present or in their outcomes in Jeddah, a major gateway city. We compared the clinical characteristics and outcomes of travel-related and locally acquired mpox cases.
methodsThis was a retrospective cohort study including 232 lab-confirmed cases in Jeddah. Cases were taken from the Health Electronic Surveillance Network (HESN) and hospital records of the first and second health clusters in Jeddah. They were grouped as travel-associated if international travel occurred within 21 days before symptom onset or the first positive test result, or as locally acquired. Then, we compared them by demographics, clinical features, disease severity, and outcomes, including hospitalization, ICU admission, hospital mortality, and length of hospital stay. Analysis of length of stay was done using multivariable linear regression, adjusting for age, sex, and facility type, and included planned sensitivity analyses.
resultsOf the 232 cases, 77 (33.2%) were travel-related, and 155 (66.8%) were locally acquired. Most patients were male (215/232, 92.7%), with a median age of 34 years. Most of the cases were mild: 227 cases (97.8%) had mild symptoms, and there were no severe cases. No one was admitted to the ICU or died in the hospital, and all patients recovered, regardless of their travel status. Travel-related cases were a bit older (median 36 vs 33 years, p = 0.006) and more often treated in private facilities (62/77, 80.5% vs 104/155, 67.1%; p = 0.048). Travel-related cases had a longer median hospital stay (21 vs 16 days, p = 0.002). After adjusting for age, sex, and facility type, international travel was not linked to length of stay (adjusted difference -0.9 days, 95% CI -3.9 to +2.1, p = 0.55), but private facility care was linked to a longer stay (+8.5 days, p < 0.001).
conclusionsIn Jeddah city, most mpox cases were mild, with no serious outcomes or hospital mortality, regardless of travel history. Differences in hospital stay were mostly associated with the type of healthcare facility, not travel status. These findings highlight that risk assessment should focus on clinical presentation and risk factors, rather than international travel, as predictors of clinical outcomes and that ensuring proper surveillance and rapid detection is crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.